Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of V114 vs PCV13 via Subcutaneous Route in Infants
jRCT2080225191Phase 3Completed
- Start
- May 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of pneumococcal 15-valent conjugate vaccine in pneumococcal disease (2 arms). Primary endpoints: Serotype-specific IgG response rate after Dose 3 (13 shared serotypes), Serotype 22F IgG response rate after Dose 3 and 2 more. Started May 2020; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on jRCT2080225191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225191.